297 related articles for article (PubMed ID: 37237486)
1. PI3K/AKT/mTOR Signaling Pathway in HPV-Driven Head and Neck Carcinogenesis: Therapeutic Implications.
Aguayo F; Perez-Dominguez F; Osorio JC; Oliva C; Calaf GM
Biology (Basel); 2023 Apr; 12(5):. PubMed ID: 37237486
[TBL] [Abstract][Full Text] [Related]
2. Repression of Human Papillomavirus Oncogene Expression under Hypoxia Is Mediated by PI3K/mTORC2/AKT Signaling.
Bossler F; Kuhn BJ; Günther T; Kraemer SJ; Khalkar P; Adrian S; Lohrey C; Holzer A; Shimobayashi M; Dürst M; Mayer A; Rösl F; Grundhoff A; Krijgsveld J; Hoppe-Seyler K; Hoppe-Seyler F
mBio; 2019 Feb; 10(1):. PubMed ID: 30755508
[TBL] [Abstract][Full Text] [Related]
3. Cellular targets of the oncoproteins encoded by the cancer associated human papillomaviruses.
Howley PM; Münger K; Romanczuk H; Scheffner M; Huibregtse JM
Princess Takamatsu Symp; 1991; 22():239-48. PubMed ID: 1668886
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease.
Kennedy EM; Kornepati AV; Goldstein M; Bogerd HP; Poling BC; Whisnant AW; Kastan MB; Cullen BR
J Virol; 2014 Oct; 88(20):11965-72. PubMed ID: 25100830
[TBL] [Abstract][Full Text] [Related]
5. PI3K/AKT/mTOR Signaling Regulates the Virus/Host Cell Crosstalk in HPV-Positive Cervical Cancer Cells.
Bossler F; Hoppe-Seyler K; Hoppe-Seyler F
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31058807
[TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus immortalization and transformation functions.
Münger K; Howley PM
Virus Res; 2002 Nov; 89(2):213-28. PubMed ID: 12445661
[TBL] [Abstract][Full Text] [Related]
7. Human Papillomavirus 16 Oncoprotein Expression Is Controlled by the Cellular Splicing Factor SRSF2 (SC35).
McFarlane M; MacDonald AI; Stevenson A; Graham SV
J Virol; 2015 May; 89(10):5276-87. PubMed ID: 25717103
[TBL] [Abstract][Full Text] [Related]
8. Reverse-phase protein array profiling of oropharyngeal cancer and significance of PIK3CA mutations in HPV-associated head and neck cancer.
Sewell A; Brown B; Biktasova A; Mills GB; Lu Y; Tyson DR; Issaeva N; Yarbrough WG
Clin Cancer Res; 2014 May; 20(9):2300-11. PubMed ID: 24599934
[TBL] [Abstract][Full Text] [Related]
9. High incidence of HPV-associated head and neck cancers in FA deficient mice is associated with E7's induction of DNA damage through its inactivation of pocket proteins.
Park JW; Shin MK; Pitot HC; Lambert PF
PLoS One; 2013; 8(9):e75056. PubMed ID: 24086435
[TBL] [Abstract][Full Text] [Related]
10. Human Papillomaviruses as Infectious Agents in Gynecological Cancers. Oncogenic Properties of Viral Proteins.
Haręża DA; Wilczyński JR; Paradowska E
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163748
[TBL] [Abstract][Full Text] [Related]
11. The Human Papillomavirus 16 E7 Oncoprotein Attenuates AKT Signaling To Promote Internal Ribosome Entry Site-Dependent Translation and Expression of c-MYC.
Strickland SW; Vande Pol S
J Virol; 2016 Jun; 90(12):5611-5621. PubMed ID: 27030265
[TBL] [Abstract][Full Text] [Related]
12. High-Risk Human Papillomavirus and Epstein-Barr Virus Coinfection: A Potential Role in Head and Neck Carcinogenesis.
Blanco R; Carrillo-Beltrán D; Corvalán AH; Aguayo F
Biology (Basel); 2021 Nov; 10(12):. PubMed ID: 34943147
[TBL] [Abstract][Full Text] [Related]
13. Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.
Brand TM; Hartmann S; Bhola NE; Li H; Zeng Y; O'Keefe RA; Ranall MV; Bandyopadhyay S; Soucheray M; Krogan NJ; Kemp C; Duvvuri U; LaVallee T; Johnson DE; Ozbun MA; Bauman JE; Grandis JR
Cancer Res; 2018 May; 78(9):2383-2395. PubMed ID: 29440171
[TBL] [Abstract][Full Text] [Related]
14. The role of RNA-binding proteins in the processing of mRNAs produced by carcinogenic papillomaviruses.
Kajitani N; Schwartz S
Semin Cancer Biol; 2022 Nov; 86(Pt 3):482-496. PubMed ID: 35181475
[TBL] [Abstract][Full Text] [Related]
15. Phylogenetic and functional analysis of sequence variation of human papillomavirus type 31 E6 and E7 oncoproteins.
Ferenczi A; Gyöngyösi E; Szalmás A; László B; Kónya J; Veress G
Infect Genet Evol; 2016 Sep; 43():94-100. PubMed ID: 27197052
[TBL] [Abstract][Full Text] [Related]
16. HPV: Molecular pathways and targets.
Gupta S; Kumar P; Das BC
Curr Probl Cancer; 2018; 42(2):161-174. PubMed ID: 29706467
[TBL] [Abstract][Full Text] [Related]
17. Cellular and molecular alterations in human epithelial cells transformed by recombinant human papillomavirus DNA.
DiPaolo JA; Popescu NC; Alvarez L; Woodworth CD
Crit Rev Oncog; 1993; 4(4):337-60. PubMed ID: 8394744
[TBL] [Abstract][Full Text] [Related]
18. A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors.
Wieking BG; Vermeer DW; Spanos WC; Lee KM; Vermeer P; Lee WT; Xu Y; Gabitzsch ES; Balcaitis S; Balint JP; Jones FR; Lee JH
Cancer Gene Ther; 2012 Oct; 19(10):667-74. PubMed ID: 22918471
[TBL] [Abstract][Full Text] [Related]
19. Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products.
Münger K; Scheffner M; Huibregtse JM; Howley PM
Cancer Surv; 1992; 12():197-217. PubMed ID: 1322242
[TBL] [Abstract][Full Text] [Related]
20. Effects of Metformin on the virus/host cell crosstalk in human papillomavirus-positive cancer cells.
Hoppe-Seyler K; Herrmann AL; Däschle A; Kuhn BJ; Strobel TD; Lohrey C; Bulkescher J; Krijgsveld J; Hoppe-Seyler F
Int J Cancer; 2021 Sep; 149(5):1137-1149. PubMed ID: 33844847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
